SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
pharmacy medicine capsule pill in production line at medical factory
Deals
Amid Novo Buy, Catalent Offloads New Jersey Facility to Ardena
European CDMO Ardena will buy Catalent’s oral solids manufacturing facility in Somerset, N.J.
October 14, 2024
 · 
1 min read
 · 
Annalee Armstrong
Pictured: Eli Lilly's headquarters in Indianapolis
Drug shortages
Lilly’s Tirzepatide Could Land Again on FDA Drug Shortage List, Opens Door for Compounders
While the regulator conducts another review into the supply of Eli Lilly’s tirzepatide, compounders will be able to continue selling their own remixed versions of the blockbuster drug.
October 14, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Pfizer office at its South San Francisco
Approvals
Pfizer Wins FDA Nod for Hemophilia Therapy Amid Activist Investor Challenge
The approval makes Pfizer’s Hympavzi the first once-weekly subcutaneous prophylactic injection for hemophilia B in the U.S., according to the company, which is currently embroiled in a row with activist investor Starboard Value.
October 14, 2024
 · 
2 min read
 · 
Tristan Manalac
3D concept photo of gene editing showing a tweezers inserting a DNA fragment into a larger strand
CRISPR
CRISPR Ex Vivo Gene Editing Gets on Target With Caribou’s Hybrid Guides
While ex vivo genome editing results in highly effective cell therapies, it can lead to off-target effects. Caribou Biosciences has come up with a novel approach for potentially more precise gene editing compared to all-RNA guides.
October 14, 2024
 · 
5 min read
 · 
Greg Slabodkin
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: Amgen, Camurus, Iterum and Lexicon
The FDA is looking at four events for the remainder of October, one of which is an advisory committee meeting for a dual SGLT inhibitor for use alongside insulin in type 1 diabetes and chronic kidney disease.
October 14, 2024
 · 
4 min read
 · 
Tristan Manalac
Opioid health risk and medical crisis with a prescription painkiller addiction epidemic concept as a group of people running away from a dangerous falling bridge of pills as a medicine addict problem with 3D illustration elements.
FDA
5 Accelerated Approvals Gone Wrong
Since its inception in 1992, the FDA’s accelerated approval pathway has helped shepherd nearly 300 new drugs to the market. However, recent years have seen a number of high-profile market withdrawals and failed confirmatory trials.
October 14, 2024
 · 
7 min read
 · 
Heather McKenzie
Set of two dart targets with arrow and dart. Vector color illustration.
Cancer
With Myriad Recent Approvals in Cancer, The Era of Bispecifics Is Here
As companies roll out data showing the power and improved safety profile of antibodies that target two antigens, analysts say the class could overtake monoclonal antibody Keytruda as the “immunotherapy backbone” of solid tumor treatment.
October 14, 2024
 · 
6 min read
 · 
Kate Goodwin
Pictured: Entrance to the FTC's office in Washington, DC
Editorial
Pressure Mounts on Novo’s $16.5B Catalent Buy Amid FTC Review
Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could increase Novo’s dominance over the hot GLP-1 market, reducing competition and increasing prices.
October 11, 2024
 · 
3 min read
 · 
Greg Slabodkin
Employees Walking In And Out Of The Door, Some Were Leaving Their Job And Some Were Being Hired At The Same Time. Full Length, Isolated On Solid Color Background. Vector, Illustration, Flat Design, Character.
Layoffs
Turnstone Biologics to Lay Off 60% of Workforce, Overhaul C-Suite
Turnstone is shifting resources to focus on clinical advancement of its selected tumor-infiltrating lymphocyte therapy as three C-suite members exit their roles.
October 11, 2024
 · 
2 min read
 · 
Angela Gabriel
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS